Kerry has just received a thumbs-up from the European Food Safety Authority (EFSA) for Acrylerase, a new enzyme that significantly lowers acrylamide levels in coffee extracts. Acrylamide is a compound formed during coffee roasting and is linked to health risks, including potential cancer.
High coffee consumption can lead to increased acrylamide exposure, raising concerns in the regulatory community. Existing methods to reduce acrylamide in coffee are often limited, struggling with raw material choices and production technologies. Kerry claims that Acrylerase outshines traditional methods by achieving up to a 90% reduction in acrylamide without affecting the coffee’s taste, aroma, or production process.
This EFSA assessment is the first of its kind for an amidase enzyme aimed at tackling acrylamide in coffee products. It reflects the growing scrutiny on acrylamide levels within the European Union, especially under the regulations established in 2017 that require food producers to monitor and manage acrylamide effectively.
Instant coffee brands can now safely incorporate Acrylerase into their products. This enzyme is derived from a genetically modified strain of E. coli. Notably, EFSA has indicated that these genetic modifications do not raise safety concerns.
Yasemin Koybasi, Kerry’s global regulatory director, emphasizes the significance of the positive EFSA opinion, calling it a major breakthrough for manufacturers seeking ways to mitigate acrylamide. The approval not only illustrates the stringent EU evaluation process but also reassures manufacturers of the enzyme’s safety in use.
Acrylamide is primarily found in coffee, coffee substitutes, and certain baked goods. In 2015, EFSA identified these as major sources of acrylamide exposure. What’s interesting about Acrylerase is that it works by breaking down acrylamide after it forms, rather than merely preventing its formation.
Dr. Marc Struhalla, CEO of c-LEcta (a subsidiary of Kerry), noted that his team engineered the enzyme to withstand the challenging conditions of coffee production, such as low pH and high temperatures. This makes Acrylerase not only effective but also straightforward to integrate into the existing production processes.
Kerry highlights that this innovation strengthens its foothold in the food enzyme sector. Acrylerase provides a solution for manufacturers grappling with both food safety and product quality challenges, while also ensuring compliance with evolving regulatory standards. This is a prime example of how innovative enzyme technology can address real-world concerns in food production.
As consumer awareness of food safety continues to grow, trends on social media show increasing discussions around acrylamide and its risks. Many people are searching for safer coffee options. By offering an effective solution, Acrylerase can cater to this demand while upholding quality and safety standards.
In light of these developments, food manufacturers are under more pressure than ever to maintain transparency and ensure their products are free from harmful substances like acrylamide. Acrylerase could be a game-changer in this effort, offering a practical and efficient method to safeguard both health and taste in coffee products.
For further insights into reducing acrylamide in food products, visit the EFSA’s dedicated page on acrylamide safety.
Source link
Kerry, Acrylerase, Acrylamide Reduction, Coffee
